Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Q2 FY19 Earnings Presentation
17 slides from Viyash Scientific's earnings presentation, Nov 2, 2018
Slide 1: Earnings Presentation Q2 & H1 FY19
Earnings Presentation Q2 & H1 FY19 NOVEMBER 2, 2018
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 3: Q2 & H1 FY19 Performance Review
Q2 & H1 FY19 Performance Review
Slide 4: Consistent performance over quarters
Consistent performance over quarters Revenues YoY “ We delivered robust 27% growth in revenue & 310 basis points margin expansion driven by improved performance Q2’19 2,517 27% across all business verticals. This has resulted in 4 fold Q2’18 1,975 increase in profitability for the quarter. This is t
Slide 5: Strong performance across businesses
Strong performance across businesses YoY% Revenue Distribution Q2’19 Q2’18 YoY% (Constant currency) Formulations 1,777 1,449 22.7% 25.7% Key Highlights Europe 902 720 25.3% 16.1% Overall business delivered strong 27.4% growth YoY Turkey 224 246 -8.8% 34.7% Emerging Markets 402 279 44.0% 32.2% ▪ API
Slide 6: Q2 & H1 FY19 Business Review
>) Sequent fae Proven Ability In Life Sciences Lo) ALIVIRA Q2 & H1 FY19 Business Review More than SeQuent Scientific Limited Pharma www.sequent.in
Slide 7: APIs
APIs 14 10 23 14+ Scaling the US Filings CEP Filings Other Regulated Pipeline capability curve Market Filings Revenues in ₹ Mn H1 FY19 H1 FY 18 YoY% Key Highlights Commercial supplies commenced to US, the largest animal health market 1,342 1,048 28.1% Largest filings amongst generic animal health co
Slide 8: Deepening key customer relationships
Deepening key customer relationships API Sales Growth Driven by Global Top 10 Top 10 28% 51% Top 10 39% Incremental sales between H1 FY 16 and H1 FY 19 from Global top 10 animal health players H1 FY16 H1 FY19 © 2018, SeQuent Scientific Limited, All Rights Reserved 8
Slide 9: Acquired EU-GMP API facility at Mahad
Acquired EU-GMP API facility at Mahad Comprehensive manufacturing facility spread over 6 acres of land with 23 reactors having cumulative capacity of 76KL Approved by EU-GMP & COFEPRIS Mexico, WHO-Geneva approval expected shortly Complements our current manufacturing at Vizag (USFDA Major products:
Slide 10: Formulations
Formulations Leading revenue 35+ 80+ 20+ 50%+ Products Under Countries with Products Sales to regulated driver Development marketing presence Launched markets Revenues in ₹ Mn Key Highlights H1 FY19 H1 FY 18 YoY% Robust growth across geographies, driven by 20+ launches and improved market share 3,52
Slide 11: Consistent delivery
Sequent Proven Ability In Life Sciences More than Pharma Consistent delivery ALIVIRA SeQuent Scientific Limited www.sequent.in
Slide 12: Delivering consistent outcome over 10 quarters
Delivering consistent outcome over 10 quarters All values in ₹ Mn Revenue Revenue 2352 2517 4869 1943 1,700 1975 2,090 2249 2,003 2328 3918 1,097 2,797 Q1 Q2 Q3 Q4 H1 ‘17 H1 ‘18 H1 ‘19 EBITDA EBITDA 12.7% 13.2% 10.6% 10.0% 9.6% 320 9.5% 11.2% 570 7.6% 250 5.2% 308 6.2% 226 224 147 190 198 156 337 68
Slide 13: Consolidated Income Statement
Consolidated Income Statement All values in ₹ Mn Q2'19 Q2'19 Q1’19 Q2'18 H1’19 H1’19 H1’18 FY18 PARTICULARS Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Audited Revenue from Operations 2,517 2,517 2,352 1,975 4,869 4,869 3,918 8,494 Material Consumption (1,310) (1,317) (1,26
Slide 14: Key Balance Sheet items
Key Balance Sheet items All values in ₹ Mn Net Debt to Equity Particulars Mar-18 Sep-18 Comments 0.44 Shareholders' funds 6,476 6,254 Fair valuation of Strides / 0.38 Solara shares 0.27 Minority Interest 370 416 Borrowings 3,049 3,405 Mahad acquisition FY17 FY18 FY19 Cash 598 648 Net debt to EBITDA
Slide 15: FY 19 Drivers
Sequent Proven Ability In Life Sciences More than Pharma FY 19 Drivers ALIVIRA SeQuent Scientific Limited www.sequent.in
Slide 16: FY19 Drivers
FY19 Drivers APIs Formulations H1 Performance FY 19 ▪ API business to ▪ Maintain above ▪ Revenue up 27% YoY accelerate, driven by industry growth ▪ EBITDA expansion 310 Business on track commercialisation in across geographies bps YoY to achieve FY19 US and Mahad ▪ Bremer to achieve ▪ Regulatory tai
Slide 17: Thank You
Sequent Proven Ability In Life Sciences ALIVIRA Thank You SeQuent Scientific Limited CIN: L99999MH1985PLC036685 Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22,Wagle Industrial Estate, Thane (W) - 400 604, Maharashtra Tel No: +91 22 4111 4777 | Website: www.sequent.in | E